IBDEI14O ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18839,0)
 ;;=D06.7^^94^916^39
 ;;^UTILITY(U,$J,358.3,18839,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18839,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,18839,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,18839,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,18840,0)
 ;;=D04.9^^94^916^42
 ;;^UTILITY(U,$J,358.3,18840,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18840,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,18840,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,18840,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,18841,0)
 ;;=C91.11^^94^916^45
 ;;^UTILITY(U,$J,358.3,18841,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18841,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,18841,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,18841,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,18842,0)
 ;;=C91.10^^94^916^46
 ;;^UTILITY(U,$J,358.3,18842,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18842,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,18842,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,18842,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,18843,0)
 ;;=C92.11^^94^916^47
 ;;^UTILITY(U,$J,358.3,18843,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18843,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,18843,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,18843,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,18844,0)
 ;;=C92.10^^94^916^48
 ;;^UTILITY(U,$J,358.3,18844,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18844,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,18844,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,18844,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,18845,0)
 ;;=D47.1^^94^916^49
 ;;^UTILITY(U,$J,358.3,18845,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18845,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,18845,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,18845,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,18846,0)
 ;;=C82.69^^94^916^50
 ;;^UTILITY(U,$J,358.3,18846,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18846,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,18846,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,18846,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,18847,0)
 ;;=C82.60^^94^916^51
 ;;^UTILITY(U,$J,358.3,18847,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18847,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,18847,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,18847,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,18848,0)
 ;;=D56.2^^94^916^52
 ;;^UTILITY(U,$J,358.3,18848,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18848,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,18848,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,18848,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,18849,0)
 ;;=D75.9^^94^916^53
 ;;^UTILITY(U,$J,358.3,18849,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18849,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,18849,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,18849,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,18850,0)
 ;;=D59.0^^94^916^56
 ;;^UTILITY(U,$J,358.3,18850,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18850,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,18850,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,18850,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,18851,0)
 ;;=D59.2^^94^916^57
 ;;^UTILITY(U,$J,358.3,18851,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18851,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
